The transaction includes a 55000000 USD purchase price paid over five years, including an initial 10000000 USD payment at closing, plus up to 95000000 USD in contingent payments based on future performance. Herbalife also obtained a call option to acquire Bioniq LAB, a separate platform focused on small molecules and peptides. Transaction expected to close in Q2 2026, subject to customary closing conditions and regulatory approvals.